宏基因组学测序技术在肝硬化脓毒症中的应用

贝小歌; 陈金军; 黎倍伶

doi:10.3969/j.issn.1001-5256.2021.09.041

宏基因组学测序技术在肝硬化脓毒症中的应用

DOI: 10.3969/j.issn.1001-5256.2021.09.041

南方医科大学南方医院肝病中心，广州 510515

基金项目:

国家科技部重大专项 (2018ZX10723203);

国家科技部重大专项 (2018ZX10302206);

国家重点研发计划 (2017YFC0908100);

广东省珠江人才计划 (2017BT01S131);

南方医院"临床研究专项" (2018CR037);

南方医院"临床研究专项" (2020CR026);

南方医科大学临床启动计划 (LC2019ZD006)

利益冲突声明：所有作者均声明不存在利益冲突。

作者贡献声明：贝小歌负责拟定写作思路，撰写论文；陈金军、黎倍伶参与修改论文，指导撰写文章并最后定稿。

详细信息

通信作者:
陈金军，chjj@smu.edu.cn

黎倍伶，lbling123@163.com

中图分类号: R575.2
计量
- 文章访问数: 493
- HTML全文浏览量: 192
- PDF下载量: 45
- 被引次数: 0
出版历程
- 收稿日期: 2021-02-03
- 录用日期: 2021-05-07
- 出版日期: 2021-09-20

Application of metagenomic next-generation sequencing in sepsis in liver cirrhosis

Liver Disease Center, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China

Research funding:

National Science and Technology Major Project (2018ZX10723203);

National Science and Technology Major Project (2018ZX10302206);

National Key Research and Development Program of China (2017YFC0908100);

Local Innovative and Research Teams Project of Guangdong Pearl River Talents Program (2017BT01S131);

Clinical Research Program of Nanfang Hospital (2018CR037);

Clinical Research Program of Nanfang Hospital (2020CR026);

Clinical Research Program of Nanfang Hospital, Southern Medical University (LC2019ZD006)

摘要

摘要: 肝硬化患者由于持续的全身性炎症和免疫抑制状态，容易发生细菌感染，严重时可进展为脓毒症。早期有效的抗生素治疗是改善脓毒症患者预后的关键。简述了肝硬化患者发生脓毒症的病理生理机制及诊疗现状。认为宏基因组学测序技术可用于指导脓毒症的有效抗菌治疗。
- 肝硬化 /
- 脓毒症 /
- 宏基因组学 /
- 序列分析
Abstract: Due to persistent systemic inflammation and immunosuppressive conditions, patients with liver cirrhosis are susceptible to bacterial infection, which may progress to sepsis without proper control. Early effective antibiotic therapy is the key to improving the prognosis of patients with sepsis. This article briefly describes the pathophysiological mechanism of sepsis in patients with liver cirrhosis and the current status of the diagnosis and treatment of sepsis, and it is pointed out that metagenomic next-generation sequencing can be used to guide effective antibacterial treatment of sepsis.
- Liver Cirrhosis /
- Sepsis /
- Metagenomics /
- Sequence Analysis

HTML全文

参考文献(41)

[1]	FERNÁNDEZ J, PRADO V, TREBICKA J, et al. Multidrug-resistant bacterial infections in patients with decompensated cirrhosis and with acute-on-chronic liver failure in Europe[J]. J Hepatol, 2019, 70(3): 398-411. DOI: 10.1016/j.jhep.2018.10.027.
[2]	FERNÁNDEZ J, ACEVEDO J, CASTRO M, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: A prospective study[J]. Hepatology, 2012, 55(5): 1551-1561. DOI: 10.1002/hep.25532.
[3]	ARVANITI V, D'AMICO G, FEDE G, et al. Infections in patients with cirrhosis increase mortality four-fold and should be used in determining prognosis[J]. Gastroenterology, 2010, 139(4): 1246-1256.e1-e5. DOI: 10.1053/j.gastro.2010.06.019.
[4]	QAZI SA, STOLL BJ. Neonatal sepsis: A major global public health challenge[J]. Pediatr Infect Dis J, 2009, 28(1 Suppl): s1-s2. DOI: 10.1097/INF.0b013e31819587a9.
[5]	ZHONG Y, XU F, WU J, et al. Application of next generation sequencing in laboratory medicine[J]. Ann Lab Med, 2021, 41(1): 25-43. DOI: 10.3343/alm.2021.41.1.25.
[6]	CAMPBELL KA, TRIVEDI HD, CHOPRA S. Infections in cirrhosis: A guide for the clinician[J]. Am J Med, 2021, 134(6): 727-734. DOI: 10.1016/j.amjmed.2021.01.015.
[7]	LEBOSSÉ F, GUDD C, TUNC E, et al. CD8⁺T cells from patients with cirrhosis display a phenotype that may contribute to cirrhosis-associated immune dysfunction[J]. EBio Medicine, 2019, 49: 258-268. DOI: 10.1016/j.ebiom.2019.10.011.
[8]	BERNSMEIER C, POP OT, SINGANAYAGAM A, et al. Patients with acute-on-chronic liver failure have increased numbers of regulatory immune cells expressing the receptor tyrosine kinase MERTK[J]. Gastroenterology, 2015, 148(3): 603-615.e14. DOI: 10.1053/j.gastro.2014.11.045.
[9]	BOUSSIF A, ROLAS L, WEISS E, et al. Impaired intracellular signaling, myeloperoxidase release and bactericidal activity of neutrophils from patients with alcoholic cirrhosis[J]. J Hepatol, 2016, 64(5): 1041-1048. DOI: 10.1016/j.jhep.2015.12.005.
[10]	LI BL, GAO YH, WANG XB, et al. Clinical features and outcomes of bacterascites in cirrhotic patients: A retrospective, multicentre study[J]. Liver Int, 2020, 40(6): 1447-1456. DOI: 10.1111/liv.14418.
[11]	ENGELMANN C, BECKER C, BOLDT A, et al. Ascites' neutrophil function is significantly impaired in patients with decompensated cirrhosis but can be restored by autologous plasma incubation[J]. Sci Rep, 2016, 6: 37926. DOI: 10.1038/srep37926.
[12]	NICOLETTI A, PONZIANI FR, BIOLATO M, et al. Intestinal permeability in the pathogenesis of liver damage: From non-alcoholic fatty liver disease to liver transplantation[J]. World J Gastroenterol, 2019, 25(33): 4814-4834. DOI: 10.3748/wjg.v25.i33.4814.
[13]	OKUMURA R, TAKEDA K. Maintenance of intestinal homeostasis by mucosal barriers[J]. Inflamm Regen, 2018, 38: 5. DOI: 10.1186/s41232-018-0063-z.
[14]	DI PASCOLI M, SACERDOTI D, PONTISSO P, et al. Molecular mechanisms leading to splanchnic vasodilation in liver cirrhosis[J]. J Vasc Res, 2017, 54(2): 92-99. DOI: 10.1159/000462974.
[15]	WANG L, FOUTS DE, STÄRKEL P, et al. Intestinal REG3 lectins protect against alcoholic steatohepatitis by reducing mucosa-associated microbiota and preventing bacterial translocation[J]. Cell Host Microbe, 2016, 19(2): 227-239. DOI: 10.1016/j.chom.2016.01.003.
[16]	GHOSH G, JESUDIAN AB. Small intestinal bacterial overgrowth in patients with cirrhosis[J]. J Clin Exp Hepatol, 2019, 9(2): 257-267. DOI: 10.1016/j.jceh.2018.08.006.
[17]	LAPIDOT Y, AMIR A, NOSENKO R, et al. Alterations in the gut microbiome in the progression of cirrhosis to hepatocellular carcinoma[J]. mSystems, 2020, 5(3). DOI: 10.1128/mSystems.00153-20.
[18]	DEL CAMPO JA, GALLEGO P, GRANDE L. Role of inflammatory response in liver diseases: Therapeutic strategies[J]. World J Hepatol, 2018, 10(1): 1-7. DOI: 10.4254/wjh.v10.i1.1.
[19]	ELCHANINOV AV, FATKHUDINOV TK, VISHNYAKOVA PA, et al. Phenotypical and functional polymorphism of liver resident macrophages[J]. Cells, 2019, 8(9): 1032. DOI: 10.3390/cells8091032.
[20]	CLÀRIA J, STAUBER RE, COENRAAD MJ, et al. Systemic inflammation in decompensated cirrhosis: Characterization and role in acute-on-chronic liver failure[J]. Hepatology, 2016, 64(4): 1249-1264. DOI: 10.1002/hep.28740.
[21]	SINGER M, DEUTSCHMAN CS, SEYMOUR CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3)[J]. JAMA, 2016, 315(8): 801-810. DOI: 10.1001/jama.2016.0287.
[22]	VARON J, BARON RM. A current appraisal of evidence for the approach to sepsis and septic shock[J]. Ther Adv Infect Dis, 2019, 6: 2049936119856517. DOI: 10.1177/2049936119856517.
[23]	LIU ZC, YANG XS. Nutritional support treatment strategies for sepsis[J]. Chin J Dig Surg, 2019, 18(10): 920-923. DOI: 10.3760/cma.j.issn.1673-9752.2019.010.006. 刘正才, 杨西胜. 脓毒症营养支持治疗策略[J]. 中华消化外科杂志, 2019, 18(10): 920-923. DOI: 10.3760/cma.j.issn.1673-9752.2019.010.006.
[24]	SEYMOUR CW, GESTEN F, PRESCOTT HC, et al. Time to treatment and mortality during mandated emergency care for sepsis[J]. N Engl J Med, 2017, 376(23): 2235-2244. DOI: 10.1056/NEJMoa1703058.
[25]	WHILES BB, DEIS AS, SIMPSON SQ. Increased time to initial antimicrobial administration is associated with progression to septic shock in severe sepsis patients[J]. Crit Care Med, 2017, 45(4): 623-629. DOI: 10.1097/CCM.0000000000002262.
[26]	RHODES A, EVANS LE, ALHAZZANI W, et al. Surviving sepsis campaign: International guidelines for management of sepsis and septic shock: 2016[J]. Crit Care Med, 2017, 45(3): 486-552. DOI: 10.1097/CCM.0000000000002255.
[27]	BARTOLETTI M, GIANNELLA M, LEWIS R, et al. A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients[J]. Clin Microbiol Infect, 2018, 24(5): 546. e1-546. e8. DOI: 10.1016/j.cmi.2017.08.001.
[28]	PIANO S, SINGH V, CARACENI P, et al. Epidemiology and effects of bacterial infections in patients with cirrhosis worldwide[J]. Gastroenterology, 2019, 156(5): 1368-1380.e10. DOI: 10.1053/j.gastro.2018.12.005.
[29]	HARBARTH S, GARBINO J, PUGIN J, et al. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis[J]. Am J Med, 2003, 115(7): 529-535. DOI: 10.1016/j.amjmed.2003.07.005.
[30]	KUMAR A, ELLIS P, ARABI Y, et al. Initiation of inappropriate antimicrobial therapy results in a fivefold reduction of survival in human septic shock[J]. Chest, 2009, 136(5): 1237-1248. DOI: 10.1378/chest.09-0087.
[31]	SINGER M. Antibiotics for sepsis: Does each hour really count, or is it incestuous amplification?[J]. Am J Respir Crit Care Med, 2017, 196(7): 800-802. DOI: 10.1164/rccm.201703-0621ED.
[32]	ZHONG Y, XU F, WU J, et al. Application of next generation sequencing in laboratory medicine[J]. Ann Lab Med, 2021, 41(1): 25-43. DOI: 10.3343/alm.2021.41.1.25.
[33]	LIPPI G. Sepsis biomarkers: Past, present and future[J]. Clin Chem Lab Med, 2019, 57(9): 1281-1283. DOI: 10.1515/cclm-2018-1347.
[34]	KIM H, HUR M, MOON HW, et al. Multi-marker approach using procalcitonin, presepsin, galectin-3, and soluble suppression of tumorigenicity 2 for the prediction of mortality in sepsis[J]. Ann Intensive Care, 2017, 7(1): 27. DOI: 10.1186/s13613-017-0252-y.
[35]	PALACIOS G, DRUCE J, DU L, et al. A new arenavirus in a cluster of fatal transplant-associated diseases[J]. N Engl J Med, 2008, 358(10): 991-998. DOI: 10.1056/NEJMoa073785.
[36]	XU B, LIU L, HUANG X, et al. Metagenomic analysis of fever, thrombocytopenia and leukopenia syndrome (FTLS) in Henan Province, China: Discovery of a new bunyavirus[J]. PLoS Pathog, 2011, 7(11): e1002369. DOI: 10.1371/journal.ppat.1002369.
[37]	LANGLEY RJ, WONG HR. Early diagnosis of sepsis: Is an integrated omics approach the way forward?[J]. Mol Diagn Ther, 2017, 21(5): 525-537. DOI: 10.1007/s40291-017-0282-z.
[38]	ROZO M, SCHULLY KL, PHILIPSON C, et al. An observational study of sepsis in takeo province cambodia: An in-depth examination of pathogens causing severe infections[J]. PLoS Negl Trop Dis, 2020, 14(8): e0008381. DOI: 10.1371/journal.pntd.0008381.
[39]	GRUMAZ S, GRUMAZ C, VAINSHTEIN Y, et al. Enhanced performance of next-generation sequencing diagnostics compared with standard of care microbiological diagnostics in patients suffering from septic shock[J]. Crit Care Med, 2019, 47(5): e394- e402. DOI: 10.1097/CCM.0000000000003658.
[40]	GRUMAZ S, STEVENS P, GRUMAZ C, et al. Next-generation sequencing diagnostics of bacteremia in septic patients[J]. Genome Med, 2016, 8(1): 73. DOI: 10.1186/s13073-016-0326-8.
[41]	GRENINGER AL. The challenge of diagnostic metagenomics[J]. Expert Rev Mol Diagn, 2018, 18(7): 605-615. DOI: 10.1080/14737159.2018.1487292.